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Undiagnosed syncope is always a perplexing and challenging diagnostic problem that clinician 
face daily. Vasovagal syncope (VVS) remains the most common cause of syncope especially 
in the absence of significant  structural  heart  disease and ECG abnormalities.  Syncope is a 
frequent cause of consultation and accounts for about 3% of Emergency room admissions and 
1% to  6% hospital  admissions  in  the US [1-4].  Kenny et  al  introduced head-up tilt  table 
(HUTT)  testing  in  1986  improving  our  understanding  of  VVS  and  providing  a  useful 
diagnostic  test  with  an  acceptable  diagnostic  yield  [6]  HUTT  is  useful  to  determine  an 
individuals  susceptibility  for  VVS, allowing  reproduction  of  the  symptoms in  a  safe  and 
controlled  environment  [5].The  initial  HUTT  protocols  entailed  the  use  of  a  passive 
unmedicated orthostatic challenge, however these protocols were time consuming and had a 
low diagnostic  yield in  patients  presenting with unexplained syncope [7].                 
Almost two decades ago several investigators shortened the passive tilt phase and associated 
either isoproterenol, or nitroglycerine, to circumvent this limitation. Isoproterenol was the first 
agent  used  and  evidence  of  increased  diagnostic  yield  with  a  modest  loss  in  specificity 
particularly at doses above 2.5 mcg/min has been reported and is recommended by the latest 
ESC guidelines [5]. Low dose isoproterenol when combined with shorter duration of drug free 
HUTT  yielded  comparative  sensitivity  without  compromising  specificity  [8].Occasionally, 
isoproterenol can be associated with adverse events such as arrhythmias and angina, however 
these  events  are  rather  rare  at  mean  doses  under  2  mcg/min.  Further  studies  have 
recommended the use of low-dose isoproterenol  primarily  in patients  < 50 and nitrates  in 
patients  >  50  years  of  age  [9].                                                   
For  the  above reasons isoproterenol  is  primarily  used  in  younger  patients  presenting  with 
unexplained syncope and nitrates  have been promoted in  older  subjects.[10]  Nitrates  were 
introduced as an  alternative to isoproterenol during HUTT by Raviele et al [11] in 1993. Since 
then several investigators have reported the use of nitrates either in oral, spray or intravenous 
administration.  The precise mechanisms by which nitrates  improve the diagnostic  yield of 
HUTT  is  multifactorial  and  involve  a  complex  interaction  of  reduced  venous  return, 
baroreceptor and neurohormonal activation [5].  A central action of nitrates also has been 
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postulated  [13].  A  recent  meta-analysis  of  HUTT  in  patients  with  unexplained  syncope 
reported a significant improvement in diagnostic yield  with use of nitrates while maintaining 
specificity  compared  to  high  dose  isoproterenol  [14].                             
In this issue of the journal, Asati et al report the results of a non-randomized study comparing 
2 protocols of nitrate augmented HUTT [15].  Standard protocol included administration of 
sublingual  nitroglycerine  after  45  minutes  of  passive  or  drug  free  phase  of  HUTT,  and 
continuation  for another  15 minutes.  Protocol  B included a 5 minute  rest  phase after  the 
passive phase HUTT by returning the patient to the supine position, after which nitrates were 
administered in the supine position, and the patient was tilted for another 15 minutes in both 
arms.
The main finding of this study was that there were no significant differences between the 2 
protocols regarding diagnostic yield, specificity and time to syncope during either the passive 
or augmented HUTT phases. Similarly, there were no significant differences in specificity but 
a slight non-significant reduction in diagnostic yield was reported in protocol B during HUTT 
phase.  
This study has a small sample size and could be a limiting factor to accept these findings in 
prima  facie,  nonetheless  this  finding  may  be  hypothesis  generating  and  may  support  the 
multifaceted action  of nitrates  in improving the diagnostic  yield and specificity  of HUTT. 
Which is the best methodology to perform a reproducible HUTT protocol? This issue remains 
largely debated but the ESC 2009 provides an evidenced based recommendation regarding the 
duration,  inclination  degree  and  pharmacological  agents  that  improve  diagnostic  yield  of 
HUTT [5]. Briefly, no resting phase, i.e returning to the supine position is recommended as 
this extends unnecessarily HUTT duration and may reset baroreceptor response to orthostatic 
challenge. Similarly duration of guideline recommended HUTT protocols is between 20 to 30 
minutes. If the action of nitrates was merely venodilatory, one would have expected a lower 
positive  response  in  group 2 compared to  group1.                                      
Total HUTT duration should be around 30 minutes with a passive phase lasting between 15-20 
based on the fact that the mean time to syncope in most studies is 20 +/- 5 minutes. In the  
current study duration of HUTT was unnecessarily prolonged as it is well  established that 
longer duration does not increase diagnostic yield and prevents the wider use of HUTT due to 
limited resources. One of the initial objectives of adding pharmacological challenge during 
HUTT was to overcome the limitation of prolonged procedure times.                                
Macedo et  al  reported yet  another  modification  of nitrate  facilitated HUTT in which they 
compared standard protocol to a shortened protocol with nitrate potentiated phase without a 
passive phase. Shortened nitrate potentiated protocol was not inferior to standard protocol with 
regard  to  sensitivity,  specificity  and accuracy.  Further  more  a  shortened  protocol  allowed 
faster  diagnosis  and was better  tolerated  [16].                                         
The present study will unlikely change clinical practice, but may provide additional insight to 
our understanding of the pathophysiology and mechanisms of pharmacological augmentation 
of HUTT diagnosis of VVS. It is important to stress that the diagnosis of unexplained syncope 
remains being a clinical one and a negative HUTT does not eliminate the possibility of VVS as 
the etiology of syncope. Addition of tools such as the Calgary Syncope Symptom Score have 
been shown to provide excellent diagnostic accuracy and should be routinely used in patients 
with  recurrent  explained  syncope  and  little  evidence  of  structural  heart  disease.
In summary the current study provides newer insights into the benefits of pharmacologically 
provoked  HUTT  in  patients  with  unexplained  syncope  suggesting  that  nitrates  increase 
diagnostic yield in patients presenting with unexplained syncope.                                      
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